Advertisement

FDA Makes Plans to Correct Cancer Drug Shortages in the U.S.

Published on: 

Drug shortages in the U.S. have been an ongoing concern over the last couple of years, and have come to a head in recent months. Two cancer drugs in particular, Doxil (doxorubicin hydrochloride liposome injection) and the life-saving methotrexate are in short supply, but the FDA has made plans they say should swiftly reverse the situation.

Shortages of the medications worsened when a major manufacturing plant, Ben Venue Laboratories, shut down production due to safety concerns. To make up for the deficit, the FDA has decided to allow imports of a Doxil substitute, called Lipodox (doxorubicin hydrochloride liposome injection), which will apparently meet demand over the coming weeks. To address the methotrexate shortage, the Agency has approved another manufacturer to import a preservative-free generic version of the cancer drug to boost supplies.

Advertisement

Read the full story: http://hcp.lv/IJyGtG

Source: The Atlantic


Advertisement
Advertisement